Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial

Tino F Schwarz, Roderick A McPhee, Odile Launay, Geert Leroux-Roels, Jaak Talli, Marta Picciolato, Feng Gao, Rongman Cai, Thi Lien-Anh Nguyen, Ilse Dieussaert, Jacqueline M Miller, Alexander C Schmidt, Tino F Schwarz, Roderick A McPhee, Odile Launay, Geert Leroux-Roels, Jaak Talli, Marta Picciolato, Feng Gao, Rongman Cai, Thi Lien-Anh Nguyen, Ilse Dieussaert, Jacqueline M Miller, Alexander C Schmidt

Abstract

Background: Respiratory syncytial virus (RSV) is a common cause of respiratory tract illness and hospitalization in neonates and infants. RSV vaccination during pregnancy may protect offspring in their first months of life.

Methods: This randomized, observer-blind, multicenter, phase 2 study evaluated the immunogenicity and safety of an RSV candidate vaccine in healthy nonpregnant women aged 18-45 years. Four hundred participants were randomized (1:1:1:1) to receive a single intramuscular dose of vaccine containing 30 µg, 60 µg, or 120 µg of RSV fusion protein engineered to preferentially maintain a prefusion conformation (RSV-PreF vaccine) or placebo.

Results: Thirty days postvaccination, RSV-A neutralizing antibody geometric mean titers (GMTs) increased 3.75-, 4.42- and 4.36-fold; RSV-B neutralizing antibody GMTs 2.36-, 2.54- and 2.76-fold; and palivizumab competing antibody (PCA) concentrations 11.69-, 14.38- and 14.24-fold compared with baseline levels in the 30 µg, 60 µg, and 120 µg RSV-PreF groups, respectively. Antibody titers and PCA concentrations at day 30 were significantly higher with the 120 µg compared to the 30 µg RSV-PreF vaccine. All RSV-PreF vaccine formulations and the placebo had similar reactogenicity profiles. No serious adverse events were considered to be related to the RSV-PreF vaccine.

Conclusions: The 3 formulations of the investigational RSV-PreF vaccine were well-tolerated and induced RSV-A and RSV-B neutralizing antibodies and PCAs in healthy, nonpregnant women.

Clinical trials registration: NCT02956837.

Keywords: maternal immunization; neutralizing antibodies; nonpregnant women; palivizumab competing antibody; randomized trial; respiratory syncytial virus; safety.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Study design and procedures. Enrollment stages reflect planned enrollment figures. Abbreviations: 30 RSV-PreF/60 RSV-PreF/120 RSV-PreF, group of women who received 1 dose of the unadjuvanted respiratory syncytial virus (RSV) vaccine containing 30, 60, or 120 μg of RSV prefusion F protein; Control, group of women who received 1 dose of placebo; iSRC, internal safety review committee.
Figure 2.
Figure 2.
Flow of participants. *One participant was withdrawn due to a serious adverse event after contact 2 (day 270). Abbreviations: 30 RSV-PreF/60 RSV-PreF/120 RSV-PreF, group of women who received 1 dose of the unadjuvanted respiratory syncytial virus (RSV) vaccine containing 30, 60, or 120 μg of RSV prefusion F protein; Control, group of women who received 1 dose of placebo; SAE, serious adverse event.
Figure 3.
Figure 3.
Geometric mean respiratory syncytial virus–A neutralizing antibody titers (A), geometric mean respiratory syncytial virus–B neutralizing antibody titers (B), and geometric mean palivizumab-competing antibody concentrations (C) until day 90 (per-protocol set). Error bars represent 95% confidence intervals. The raw data for the 60 μg and 120 μg groups are so similar as to be indistinguishable in Figure 3C. Abbreviations: 30 RSV-PreF/60 RSV-PreF/120 RSV-PreF, group of women who received 1 dose of the unadjuvanted RSV vaccine containing 30, 60, or 120 μg of RSV prefusion F protein; CI, confidence interval; Control, group of women who received 1 dose of placebo; GMC, geometric mean concentration; GMT, geometric mean titer; RSV, respiratory syncytial virus.
Figure 4.
Figure 4.
Solicited injection site and general adverse events reported within 7 days after vaccination (exposed set). Error bars represent 95% confidence intervals. Abbreviations: 30 RSV-PreF/60 RSV-PreF/120 RSV-PreF, group of women who received 1 dose of the unadjuvanted respiratory syncytial virus (RSV) vaccine containing 30, 60, or 120 μg of RSV prefusion F protein; AEs, adverse events; CI, confidence interval; Control, group of women who received 1 dose of placebo.

References

    1. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 2013; 31(Suppl 2):B209–15.
    1. Shi T, McAllister DA, O’Brien KL, et al. . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017; 390:946–58.
    1. Jorquera PA, Tripp RA. Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert Rev Respir Med 2017; 11:609–15.
    1. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140:543–6.
    1. Hall CB, Weinberg GA, Iwane MK, et al. . The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588–98.
    1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344:1917–28.
    1. Iwane MK, Edwards KM, Szilagyi PG, et al. . New Vaccine Surveillance Network Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004; 113:1758–64.
    1. Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:415–20.
    1. Prescott WA Jr, Doloresco F, Brown J, Paladino JA. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 2010; 28:279–93.
    1. Schmidt AC. Progress in respiratory virus vaccine development. Semin Respir Crit Care Med 2011; 32:527–40.
    1. Abraham C, Pichichero M, Eisenberg J, Singh S. Third-trimester maternal vaccination against pertussis and pertussis antibody concentrations. Obstet Gynecol 2018; 131:364–9.
    1. Amirthalingam G, Campbell H, Ribeiro S, et al. . Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction. Clin Infect Dis 2016; 63:236–43.
    1. Lambach P, Hombach J, Ortiz JR. A global perspective of maternal influenza immunization. Vaccine 2015; 33:6376–9.
    1. Rasmussen SA, Watson AK, Kennedy ED, Broder KR, Jamieson DJ. Vaccines and pregnancy: past, present, and future. Semin Fetal Neonatal Med 2014; 19:161–9.
    1. Vojtek I, Dieussaert I, Doherty TM, et al. . Maternal immunization: where are we now and how to move forward? Ann Med 2018; 50:193–208.
    1. Demicheli V, Barale A, Rivetti A. Vaccines for women to prevent neonatal tetanus. Cochrane Database Syst Rev 2013; 5:CD002959.
    1. Roca A, Abacassamo F, Loscertales MP, et al. . Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. J Med Virol 2002; 67:616–23.
    1. Gonzalez-Reyes L, Ruiz-Arguello MB, Garcia-Barreno B, et al. . Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Nat Acad Sci U S A 2001; 98:9859–64.
    1. Magro M, Mas V, Chappell K, et al. . Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Nat Acad Sci U S A 2012; 109:3089–94.
    1. McLellan JS, Chen M, Leung S, et al. . Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013; 340:1113–7.
    1. Tian D, Battles MB, Moin SM, et al. . Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat Commun 2017; 8:1877.
    1. Blais N, Gagne M, Hamuro Y, et al. . Characterization of Pre-F-GCN4t, a modified human respiratory syncytial virus fusion protein stabilized in a noncleaved prefusion conformation. J Virol 2017; 91. doi:10.1128/JVI.02437-16
    1. Langley JM, Aggarwal N, Toma A, et al. . A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant. J Infect Dis 2017; 215:24–33.
    1. Beran J, Lickliter JD, Schwarz TF, et al. . Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women: results from 2 phase 2 trials. J Infect Dis 2018; 217:1616–25.
    1. Luchsinger V, Piedra PA, Ruiz M, et al. . Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis 2012; 54:905–12.
    1. Dewé W, Durand C, Marion S, Oostvogels L, Devaster JM, Fourneau M. A multi-criteria decision making approach to identify a vaccine formulation. J Biopharm Stat 2016; 26:352–64.
    1. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981; 98:708–15.
    1. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003; 21:3479–82.
    1. Phung E, Chang LA, Morabito KM, et al. . Epitope-specific serological assays for RSV: conformation matters. Vaccines 2019; 7. doi:10.3390/vaccines7010023
    1. Steff AM, Monroe J, Friedrich K, et al. . Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV. Nat Commun 2017; 8:1085.
    1. Mazur NI, Higgins D, Nunes MC, et al. . Respiratory Syncytial Virus Network (ReSViNET) Foundation The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis 2018; 18:e295–311.
    1. Madhi SA, Swamy GK, Muñoz F, et al. . Phase 3 PREPARE study: efficacy and safety of an RSV vaccine administered to pregnant women [abstract 1046]. In: 37th Annual Meeting of the European Society for Pediatric Infectious Diseases,Ljubljana, Slovenia, 6–11 May 2019 . Accessed 6 June 2019.
    1. Novavax. Prepare trial topline results.. Accessed 11 June 2019.
    1. Novavax. Press release. Novavax announces topline results from phase 3 Prepare trial of ResVax for prevention of RSV disease in infants via maternal immunization.. Accessed 11 June 2019.
    1. Costa-Carvalho BT, Vieria HM, Dimantas RB, et al. . Transfer of IgG subclasses across placenta in term and preterm newborns. Braz J Med Biol Res 1996; 29:201–4.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit